Titre : Intégrine bêta4

Intégrine bêta4 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Overbite
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Intégrine bêta4 : Questions médicales les plus fréquentes", "headline": "Intégrine bêta4 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Intégrine bêta4 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-20", "dateModified": "2025-04-16", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Intégrine bêta4" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Chaines bêta des intégrines", "url": "https://questionsmedicales.fr/mesh/D039641", "about": { "@type": "MedicalCondition", "name": "Chaines bêta des intégrines", "code": { "@type": "MedicalCode", "code": "D039641", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.705.408.200" } } }, "about": { "@type": "MedicalCondition", "name": "Intégrine bêta4", "alternateName": "Integrin beta4", "code": { "@type": "MedicalCode", "code": "D039663", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Wenjie Huang", "url": "https://questionsmedicales.fr/author/Wenjie%20Huang", "affiliation": { "@type": "Organization", "name": "Department of Reproductive Medicine, Liuzhou Maternity and Child Healthcare Hospital, Affiliated Women and Children's Hospital of Guangxi University of Science and Technology, Liuzhou, Guangxi, 545001, People's Republic of China." } }, { "@type": "Person", "name": "Yinxiu Chi", "url": "https://questionsmedicales.fr/author/Yinxiu%20Chi", "affiliation": { "@type": "Organization", "name": "School of Basic Medicine, Central South University, Changsha, Hunan, 410078, People's Republic of China." } }, { "@type": "Person", "name": "Jingjing Li", "url": "https://questionsmedicales.fr/author/Jingjing%20Li", "affiliation": { "@type": "Organization", "name": "Department of Reproductive Medicine, Liuzhou Maternity and Child Healthcare Hospital, Affiliated Women and Children's Hospital of Guangxi University of Science and Technology, Liuzhou, Guangxi, 545001, People's Republic of China." } }, { "@type": "Person", "name": "Jia Liu", "url": "https://questionsmedicales.fr/author/Jia%20Liu", "affiliation": { "@type": "Organization", "name": "Shenzhen Jiake Biotechnology, Shenzhen, China." } }, { "@type": "Person", "name": "Michael Bachmann", "url": "https://questionsmedicales.fr/author/Michael%20Bachmann", "affiliation": { "@type": "Organization", "name": "Department of Cell Physiology and Metabolism, University of Geneva, Centre Médical Universitaire, Rue Michel-Servet 1, 1211 Geneva 4, Switzerland." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Deep overbite reduction in adolescent patients treated with Invisalign: A retrospective analysis.", "datePublished": "2024-08-12", "url": "https://questionsmedicales.fr/article/39140923", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ajodo.2024.07.008" } }, { "@type": "ScholarlyArticle", "name": "The effect of vertical skeletal proportions on overbite changes in untreated adolescents: a longitudinal evaluation.", "datePublished": "2023-09-01", "url": "https://questionsmedicales.fr/article/37655804", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2319/042823-310.1" } }, { "@type": "ScholarlyArticle", "name": "Evaluating malocclusion patterns in children with autism spectrum disorder using the index of complexity, outcome and need: a cross-sectional study.", "datePublished": "2024-07-04", "url": "https://questionsmedicales.fr/article/38965540", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12903-024-04524-y" } }, { "@type": "ScholarlyArticle", "name": "Three-dimensional Evaluation of the Carriere Motion 3D Appliance in the treatment of Class II malocclusion.", "datePublished": "2023-08-18", "url": "https://questionsmedicales.fr/article/37598337", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ajodo.2023.05.031" } }, { "@type": "ScholarlyArticle", "name": "Does the timing of treatment affect the clinical and psychological outcomes of Twin-block therapy?", "datePublished": "2023-07-04", "url": "https://questionsmedicales.fr/article/37402907", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41432-023-00908-1" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines membranaires", "item": "https://questionsmedicales.fr/mesh/D008565" }, { "@type": "ListItem", "position": 5, "name": "Récepteurs de surface cellulaire", "item": "https://questionsmedicales.fr/mesh/D011956" }, { "@type": "ListItem", "position": 6, "name": "Récepteurs immunologiques", "item": "https://questionsmedicales.fr/mesh/D011971" }, { "@type": "ListItem", "position": 7, "name": "Intégrines", "item": "https://questionsmedicales.fr/mesh/D016023" }, { "@type": "ListItem", "position": 8, "name": "Chaines bêta des intégrines", "item": "https://questionsmedicales.fr/mesh/D039641" }, { "@type": "ListItem", "position": 9, "name": "Intégrine bêta4", "item": "https://questionsmedicales.fr/mesh/D039663" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Intégrine bêta4 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Intégrine bêta4", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-15", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Intégrine bêta4", "description": "Comment diagnostiquer une anomalie d'intégrine bêta4 ?\nQuels examens sont utilisés pour évaluer l'intégrine bêta4 ?\nY a-t-il des marqueurs associés à l'intégrine bêta4 ?\nQuels symptômes peuvent indiquer un problème d'intégrine bêta4 ?\nPeut-on détecter l'intégrine bêta4 dans le sang ?", "url": "https://questionsmedicales.fr/mesh/D039663?mesh_terms=Overbite&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Intégrine bêta4", "description": "Quels symptômes sont liés à une déficience d'intégrine bêta4 ?\nL'intégrine bêta4 affecte-t-elle la mobilité cellulaire ?\nY a-t-il des signes cliniques d'une anomalie d'intégrine bêta4 ?\nLes troubles de l'intégrine bêta4 causent-ils des douleurs ?\nL'intégrine bêta4 est-elle impliquée dans des maladies spécifiques ?", "url": "https://questionsmedicales.fr/mesh/D039663?mesh_terms=Overbite&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Intégrine bêta4", "description": "Comment prévenir les complications liées à l'intégrine bêta4 ?\nY a-t-il des mesures préventives pour les maladies associées ?\nLes vaccinations peuvent-elles aider ?\nEst-il possible de modifier son mode de vie pour prévenir les problèmes ?\nLes soins dermatologiques réguliers sont-ils importants ?", "url": "https://questionsmedicales.fr/mesh/D039663?mesh_terms=Overbite&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Intégrine bêta4", "description": "Quels traitements existent pour les anomalies d'intégrine bêta4 ?\nPeut-on utiliser des médicaments pour cibler l'intégrine bêta4 ?\nLa thérapie cellulaire peut-elle aider avec l'intégrine bêta4 ?\nY a-t-il des traitements topiques pour les problèmes cutanés ?\nLes greffes de peau sont-elles une option pour les déficiences d'intégrine ?", "url": "https://questionsmedicales.fr/mesh/D039663?mesh_terms=Overbite&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Intégrine bêta4", "description": "Quelles complications peuvent survenir avec une anomalie d'intégrine bêta4 ?\nLes anomalies d'intégrine bêta4 peuvent-elles entraîner des cancers ?\nY a-t-il des risques de complications à long terme ?\nLes complications peuvent-elles affecter d'autres systèmes ?\nComment gérer les complications liées à l'intégrine bêta4 ?", "url": "https://questionsmedicales.fr/mesh/D039663?mesh_terms=Overbite&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Intégrine bêta4", "description": "Quels sont les facteurs de risque pour les anomalies d'intégrine bêta4 ?\nL'exposition au soleil est-elle un facteur de risque ?\nLes maladies auto-immunes augmentent-elles le risque ?\nLe tabagisme est-il un facteur de risque ?\nL'âge joue-t-il un rôle dans les anomalies d'intégrine bêta4 ?", "url": "https://questionsmedicales.fr/mesh/D039663?mesh_terms=Overbite&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une anomalie d'intégrine bêta4 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses de tissus peuvent révéler des anomalies d'intégrine bêta4." } }, { "@type": "Question", "name": "Quels examens sont utilisés pour évaluer l'intégrine bêta4 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "L'immunohistochimie et la cytométrie en flux sont couramment utilisés." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs associés à l'intégrine bêta4 ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des marqueurs comme l'alpha6 intégrine sont souvent associés à l'intégrine bêta4." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème d'intégrine bêta4 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des problèmes cutanés, des troubles de la cicatrisation et des anomalies de la migration cellulaire." } }, { "@type": "Question", "name": "Peut-on détecter l'intégrine bêta4 dans le sang ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'intégrine bêta4 est principalement présente dans les tissus, pas dans le sang." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une déficience d'intégrine bêta4 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des lésions cutanées, des infections fréquentes et des problèmes de cicatrisation." } }, { "@type": "Question", "name": "L'intégrine bêta4 affecte-t-elle la mobilité cellulaire ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une déficience peut entraîner des problèmes de migration cellulaire." } }, { "@type": "Question", "name": "Y a-t-il des signes cliniques d'une anomalie d'intégrine bêta4 ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies dans la structure des tissus et des problèmes d'adhésion cellulaire." } }, { "@type": "Question", "name": "Les troubles de l'intégrine bêta4 causent-ils des douleurs ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des douleurs peuvent survenir en raison de lésions cutanées et d'infections." } }, { "@type": "Question", "name": "L'intégrine bêta4 est-elle impliquée dans des maladies spécifiques ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle est liée à des maladies comme l'épidermolyse bulleuse et certains cancers." } }, { "@type": "Question", "name": "Comment prévenir les complications liées à l'intégrine bêta4 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une bonne hygiène et des soins appropriés des plaies peuvent aider à prévenir les complications." } }, { "@type": "Question", "name": "Y a-t-il des mesures préventives pour les maladies associées ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le dépistage précoce et la surveillance régulière sont recommandés." } }, { "@type": "Question", "name": "Les vaccinations peuvent-elles aider ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les vaccinations peuvent prévenir certaines infections associées aux déficiences cutanées." } }, { "@type": "Question", "name": "Est-il possible de modifier son mode de vie pour prévenir les problèmes ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sain et une alimentation équilibrée peuvent renforcer le système immunitaire." } }, { "@type": "Question", "name": "Les soins dermatologiques réguliers sont-ils importants ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des soins dermatologiques réguliers peuvent prévenir les complications cutanées." } }, { "@type": "Question", "name": "Quels traitements existent pour les anomalies d'intégrine bêta4 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des thérapies géniques et des soins dermatologiques." } }, { "@type": "Question", "name": "Peut-on utiliser des médicaments pour cibler l'intégrine bêta4 ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des inhibiteurs spécifiques de l'intégrine bêta4 sont en cours de recherche." } }, { "@type": "Question", "name": "La thérapie cellulaire peut-elle aider avec l'intégrine bêta4 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la thérapie cellulaire peut améliorer la fonction des cellules affectées." } }, { "@type": "Question", "name": "Y a-t-il des traitements topiques pour les problèmes cutanés ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des crèmes et des onguents peuvent aider à traiter les lésions cutanées." } }, { "@type": "Question", "name": "Les greffes de peau sont-elles une option pour les déficiences d'intégrine ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les greffes de peau peuvent être nécessaires dans les cas graves." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec une anomalie d'intégrine bêta4 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des infections, des cicatrices hypertrophiques et des problèmes de cicatrisation." } }, { "@type": "Question", "name": "Les anomalies d'intégrine bêta4 peuvent-elles entraîner des cancers ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines anomalies sont associées à un risque accru de cancers cutanés." } }, { "@type": "Question", "name": "Y a-t-il des risques de complications à long terme ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications chroniques peuvent affecter la qualité de vie." } }, { "@type": "Question", "name": "Les complications peuvent-elles affecter d'autres systèmes ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications peuvent également toucher le système immunitaire et les organes." } }, { "@type": "Question", "name": "Comment gérer les complications liées à l'intégrine bêta4 ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Une gestion multidisciplinaire est souvent nécessaire pour traiter les complications." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les anomalies d'intégrine bêta4 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des antécédents familiaux, des maladies génétiques et des facteurs environnementaux." } }, { "@type": "Question", "name": "L'exposition au soleil est-elle un facteur de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition excessive au soleil peut aggraver les problèmes cutanés liés à l'intégrine." } }, { "@type": "Question", "name": "Les maladies auto-immunes augmentent-elles le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines maladies auto-immunes peuvent être associées à des anomalies d'intégrine." } }, { "@type": "Question", "name": "Le tabagisme est-il un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut affecter la santé cutanée et augmenter le risque d'infections." } }, { "@type": "Question", "name": "L'âge joue-t-il un rôle dans les anomalies d'intégrine bêta4 ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le vieillissement peut affecter la fonction des intégrines et la santé cutanée." } } ] } ] }

Sources (86 au total)

Deep overbite reduction in adolescent patients treated with Invisalign: A retrospective analysis.

Data regarding the efficacy of deep overbite correction with clear aligner therapy in adolescent patients are lacking. This study aimed to investigate the efficacy of deep overbite reduction in adoles... This retrospective study investigated a sample of 102 patients aged 10-17 years from a large database. All patients had completed wear of a prescribed series of Invisalign aligners with planned overbi... A total of 102 patients with a mean ± standard deviation age of 13.94 ± 1.53 years satisfied the selection criteria. A mean ± standard deviation of 41.38 ± 30.43% of the predicted overbite reduction w... The average achieved overbite was less than half of what was planned by the orthodontists via the ClinCheck facility. The age grouping, the provision of bite ramps, and the G8 protocol appear to have ...

The effect of vertical skeletal proportions on overbite changes in untreated adolescents: a longitudinal evaluation.

To evaluate the change in overbite within an untreated cohort from 9 to 18 years of age and to compare age-related changes in overbite depth based on vertical skeletal proportion.... Lateral cephalograms were obtained from the American Association of Orthodontists Foundation (AAOF) Craniofacial Growth Legacy Collection Project. All cephalometric outcome measures were assessed at a... A total of 130 subjects from the Denver, Bolton Brush, and Oregon Growth Studies were included. Overbite was relatively constant from T1 to T3 irrespective of facial type, with a minor decrease (0.15 ... In hyperdivergent subjects, a marginal decrease in overbite was observed from 9 to 18 years of age, with a transient increase from the period spanning 9-11 years to 13-15 years, which was negated in l...

Evaluating malocclusion patterns in children with autism spectrum disorder using the index of complexity, outcome and need: a cross-sectional study.

The purpose of this study was to evaluate the complexity of malocclusion and existing patterns in children with autism spectrum disorders (ASD) using the index of complexity, outcome and need (ICON).... This cross-sectional study included children diagnosed with ASD, aged 9-15 years. A group of healthy children with the same demographic characteristics was randomly selected as the control group. Malo... A total of 324 children, divided into ASD (162) and control (162) groups, comprised the study population. Our results demonstrated that the average overall ICON score was significantly higher in the A... ASD children obtained significantly higher overall ICON scores, indicating more complex and severe malocclusions. These children also exhibited a greater tendency towards Class II and III malocclusion...

Three-dimensional Evaluation of the Carriere Motion 3D Appliance in the treatment of Class II malocclusion.

This study aimed to quantify the outcomes of adolescent patients with Class II malocclusion treated with the Carriere Motion 3D Appliance (CMA) combined with full fixed appliances.... Cone-beam computed tomography scans of 22 patients were available before orthodontic treatment (T1), at removal of the CMA (T2), and posttreatment (T3). The average age of the patients was 13.5 ± 1.6 ... Changes were analyzed with 1 sample t tests using the mean differences during the CMA phase (T1 to T2) and total treatment time (T1 to T3). Significant skeletal changes included a slight reduction of ... The CMA is an effective treatment modality for Class II correction in growing patients because of a combination of mesial movement of the mandibular molar, distal rotation of the maxillary molar, and ...

Does the timing of treatment affect the clinical and psychological outcomes of Twin-block therapy?

This study is a multicenter, two-arm parallel randomized control trial carried out across 3 hospital orthodontic units. A total of 75 patients participated in the study, with 41 randomly allocated in ... In total, 41 boys and 34 girls were included in the study. Ages for the boys ranged from within 1 month of their 12th birthday to 13.5 years old. For the girls, the range was from within 1 month of th... SPSS Version 25 software was used to undertake the data analysis. No formal statistical testing was undertaken. To analyze and compare the scores between the two groups, independent t-tests were used.... As only the ITG were in treatment over the periods of DC1-DC2 a comparison of the clinical outcomes cannot be made. With regards to the psychological outcome, no statically significant impact was note...

Effects of fixed functional orthodontic treatment in hypodivergent and hyperdivergent class II patients-a retrospective cephalometric investigation.

To compare skeletal and dentoalveolar changes after orthodontic treatment of class II malocclusion in patients with hypodivergent and hyperdivergent growth patterns through cast splint fixed functiona... N = 42 out of n = 47 patients with mandibular plane angles < 34° or ≥ 34° were divided into a hypodivergent (n = 24) and a hyperdivergent (n = 18) group. All patients received a single-step mandibular... Hypodivergent and hyperdivergent patients showed different treatment outcomes, but significant differences existed only for overbite and interincisal angle. Nearly all measurements suggested similar t... Treatment with FFA causes similar skeletal and dentoalveolar effects in hypodivergent and in hyperdivergent patients. The correction of overjet and molar relationship is mainly caused by dentoalveolar... Hyperdivergent patients do not respond unfavorably to FFA treatment compared to hypodivergent patients. Lower incisor protrusion occurs more pronounced in hypodivergent patients. The growth pattern ou...

Dentofacial effects of miniscrew-anchored maxillary protraction on prepubertal children with maxillary deficiency: a randomized controlled trial.

The introduction of bone-anchored maxillary protraction eliminated the side effects of facemask in the early treatment of patients with maxillary retrusion. This study aimed to evaluate the effects of... Forty growing patients with Class III malocclusion and retrognathic maxilla were randomly allocated into two groups: treated and control groups. In the treated group, patients were treated with full-t... Forty patients agreed to participate, and 30 of them completed the study (treated group, n = 17; control group, n = 13). The average treatment duration was 11.9 months. MAMP resulted in a significant ... Within the limitations of this study and high attrition rate, the MAMP protocol can effectively increase maxillary forward growth with good control over the growth of the mandible antero-posteriorly a...

Evaluation of the predicted vs. achieved occlusal outcomes with the Invisalign® appliance: A retrospective investigation of adult patients.

The aim of this study was to investigate the relationship between occlusal contacts, overbite, transverse expansion, and the buccolingual inclination of the teeth with reference to the predicted treat... The occlusal contacts, overbite, the buccolingual inclination and transverse expansion of the maxillary arch of adult patients satisfying inclusion and exclusion criteria were measured at the initial ... Thirty-three patients, who commenced treatment between 2013 and 2018 and satisfied inclusion/exclusion criteria were evaluated. An overall loss of posterior contact was recorded and highlighted by a s... In mild-to-moderate Class I malocclusions, treatment using the Invisalign® appliance resulted in an overall loss of posterior contact. The loss of occlusal contact was correlated with deficiencies in ...

Normal occlusion in maturational life process.

An increase in life expectancy was observed in the past years. Consequently, the knowledge of the maturational changes in the occlusion is highly important to guide clinicians during treatment plannin... In this article, the occlusal and facial aging changes occurred during almost 50 years of follow-up are described. A normal occlusion sample from Bauru Dental School, University of São Paulo, Brazil, ... Maturational changes in non-treated individuals were very delicate. Mandibular crowding, decrease in the overbite, changes in the maxillary second molar position, increase in the clinical crown length... Compared to the remarkable facial and skin changes during aging, the occlusion seems to be the most stable feature of the face during the aging process.... An adequate oral care throughout lifetime makes the smile the best memory of youth at mature ages....

Conventional and self-ligating lingual orthodontic treatment outcomes in Class I nonextraction patients: A comparative study with the American Board of Orthodontics Objective Grading System.

This study aimed to assess and compare the duration and outcomes of orthodontic treatment with conventional and self-ligating lingual fixed appliances with the American Board of Orthodontics (ABO) Obj... Thirty consecutive patients with a complete dentition and Angle Class I malocclusion treated with a conventional lingual bracket system (STb; Ormco, Glendora, Calif) or self-ligating lingual bracket s... The conventional group had a mean treatment time of 2.10 ± 0.69 years, and the self-ligating group had a treatment duration of 1.68 ± 0.48 years (P >0.05). The mean posttreatment ABO scores in the con... The design of the lingual appliances used in this study did not influence the treatment duration and the total ABO scores in treating patients with a Class I relationship in this sample. Both types of...